Moleculin Announces Breakthrough Discovery for its WP1066
December 04, 2018 07:30 ET
|
Moleculin Biotech, Inc.
WP1066 shown to counteract resistance to checkpoint blockades HOUSTON, Dec. 04, 2018 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage...
Moleculin Announces New Data Further Supporting Its Lead Drug for Treating Pancreatic Cancer
November 28, 2018 07:30 ET
|
Moleculin Biotech, Inc.
WP1732 shown to accumulate beneficially in pancreas HOUSTON, Nov. 28, 2018 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage...
Moleculin Requests FDA Meeting Regarding IND for New Cancer Drug
November 15, 2018 07:30 ET
|
Moleculin Biotech, Inc.
Testing confirms ability of WP1732 to target pancreatic cancer HOUSTON, Nov. 15, 2018 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage...
Moleculin Biotech, Inc. Reports Financial Results for the Third Quarter Ended September 30, 2018
November 13, 2018 07:30 ET
|
Moleculin Biotech, Inc.
HOUSTON, Nov. 13, 2018 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (NASDAQ: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug...
Moleculin Announces New Independent Study Expands Potential Use of Its Pancreatic Drug Candidate WP1122
November 08, 2018 07:30 ET
|
Moleculin Biotech, Inc.
Documented potential for drug candidate with characteristics like WP1122 to reverse immune suppression HOUSTON, Nov. 08, 2018 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX)...
Moleculin Announces Significant Milestone Achieved in Glioblastoma Trial
November 01, 2018 07:30 ET
|
Moleculin Biotech, Inc.
WP1066 demonstrating drug bioavailability in on-going Phase 1 clinical trial HOUSTON, Nov. 01, 2018 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a...
Moleculin Announces Positive Data on WP1066 in Pre-Clinical Trials
October 25, 2018 07:30 ET
|
Moleculin Biotech, Inc.
HOUSTON, Oct. 25, 2018 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug...
Moleculin Announces New Data Discovery Confirming Significant Increase in Potential to Starve Cancerous Tumors
October 10, 2018 07:30 ET
|
Moleculin Biotech, Inc.
Data to be Presented at Neuro-Oncology Annual Scientific Meeting HOUSTON, Oct. 10, 2018 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage...
Moleculin’s Brain Cancer Drug Candidate Begins Patient Dosing at Clinical Trial Being Conducted at MD Anderson
September 13, 2018 07:30 ET
|
Moleculin Biotech, Inc.
Small molecule lead drug candidate blocks a critical target for tumors and crosses the blood brain barrier; begins first brain cancer patient dosing in clinical trial at MD Anderson Cancer Center ...
Moleculin Biotech, Inc. Reports Financial Results for the Second Quarter Ended June 30, 2018
August 13, 2018 07:30 ET
|
Moleculin Biotech, Inc.
HOUSTON, Aug. 13, 2018 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (NASDAQ: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug...